Best Practices in the CDMO Selection Process

We are pleased to bring you a new series on “Best Practices in the CDMO Selection Process”

Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons, including: a) limited internal know-how and capacity to manufacture API according to Good Manufacturing Practice (GMP) or b) to reduce costs and timelines.

The CDMO series provides sound advice to agile biotech companies in identifying and selecting the right Contract Development and Manufacturing Organization (CDMO) for advancing the development of their product(s), in conjunction with successfully managing a chosen CDMO to meet the company’s expectations.

In these articles, we will explore the common reasons why a company might consider engaging a CDMO. We will focus on how to the evaluate CDMOs, detail the best practices for working with a CDMO to ensure the success of your product development, and more.

Why—and When—to Use a CDMO

In this 1st article of the series, we explore three common reasons why a company might consider engaging a CDMO.

Determine Your Priorities to Finding the Right CDMO

In this 2nd article of the series, we detail the best practices for working with a CDMO to ensure the success of your product development.

What to Look for in a CDMO

In this 3rd article of the series, we focus on the evaluation of a few identified CDMOs. There are several factors to consider and while some may be subjective to your company’s needs and culture, most should be quantifiable and tracked in a spreadsheet that lets you compare potential CDMOs in a like-for-like way.

Critical Quality Attributes for Drug Products

In this 4th article in the series, we explore the importance of Critical Quality Attributes (CQAs) in the drug development lifecycle and why it is vital that your selected CDMO is capable of addressing them.

How to Choose the Right Analytical Methods

In this 5th article of the series, we focus on the analytical method development around your biologics. Analytical method development is an important component of biologics development and the control of quality attributes that affect product performance and stability is critical to success.

More CDMO Resources

2023 MedTech Contract Manufacturing Report

The 2023 MedTech Contract Manufacturing Report is now available! Access this deep study and analysis of the current trends in the U.S. Medical Device outsourcing industry conducted by Alira Health in collaboration with MassMEDIC. The report investigates and measures the headwinds, challenges, and threats faced by medical device outsourcing and provides insights into how CDMOs will keep growing in 2023.

Access the 2023 MedTech Contract Manufacturing Report.